A single-agent, titrate-slowly approach to appetite-led fat loss built around one GLP-1 — the lowest-complexity place to start.
The most evidence-backed fat-loss protocol is also the simplest: one GLP-1 receptor agonist, started low and titrated up over weeks to manage nausea. This stack deliberately avoids combining incretins — stacking two GLP-1/GIP agonists adds side effects without proportionate benefit and is flagged as an avoid-pair on the compound pages.
Tirzepatide is the anchor for its dual GIP/GLP-1 mechanism and strong Phase-3 weight data. L-carnitine is an optional metabolic support some people add for fatty-acid transport during a calorie deficit; the human fat-loss evidence for it is modest, so it sits as optional, not core.
Run alongside adequate protein and resistance training to preserve lean mass — the GLP-1 does nothing to protect muscle on its own.
| Compound | Role | Dose | Frequency |
|---|---|---|---|
| Tirzepatide Dual GIP/GLP-1 anchor; start low to manage GI side effects. | Primary | 2.5mg/week, titrate up every 4 weeks as tolerated | Once weekly (same day each week) |
| L-Carnitine Optional fatty-acid-transport support during a deficit. | Optional | 50-200mg daily | Once daily or pre-workout |